Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer.
Syed, N, Coley, HM, Sehouli, J, Koensgen, D, Mustea, A, Szlosarek, P, McNeish, I, Blagden, SP, Schmid, P and Lovell, DP (2011) Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer. Cancer Res, 71 (9). pp. 3317-3327.
Syed,_Coley_et_al._2011.pdf - Accepted version Manuscript
Available under License : See the attached licence file.
Resistance to platinum- and taxane-based chemotherapy remains a major clinical impediment to effective management of epithelial ovarian cancer (EOC). To gain insights into resistance mechanisms, we compared gene and confirmed expression patterns of novel EOC cell lines selected for paclitaxel and carboplatin resistance. Here, we report that resistance can be conferred by downregulation of the Polo-like kinase Plk2. Mechanistic investigations revealed that downregulation occurred at the level of transcription via associated DNA methylation of the CpG island in the Plk2 gene promoter in cell lines, primary tumors, and patient sera. Inhibitory RNA (RNAi)-mediated knockdown and ectopic overexpression established a critical functional role for Plk2 in determining apoptotic sensitivity to paclitaxel and carboplatin. In drug-resistant human EOC cell lines, Plk2 promoter methylation varied with the degree of drug resistance and transcriptional silencing of the promoter. RNAi-dependent knockdown of Plk2 abrogated G(2)-M cell-cycle blockade by paclitaxel, conferring resistance to both paclitaxel and platinum. Conversely, ectopic expression of Plk2 restored sensitivity to G(2)-M cell-cycle blockade and cytotoxicity triggered by paclitaxel. In clinical cases, DNA methylation of the Plk2 CpG island in tumor tissue was associated with a higher risk of relapse in patients treated postoperatively with carboplatin and paclitaxel (P = 0.003). This trend was also reflected in the analysis of matched serum samples. Taken together, our results implicate Plk2 as a clinically important determinant of chemosensitivity, in support of the candidacy of Plk2 as a theranostic marker to inform EOC management.
|Divisions :||Faculty of Health and Medical Sciences > School of Biosciences and Medicine > Department of Biochemical Sciences|
|Date :||1 May 2011|
|Identification Number :||10.1158/0008-5472.CAN-10-2048|
|Uncontrolled Keywords :||Carboplatin, Cell Division, Cell Line, Tumor, Cisplatin, CpG Islands, DNA Methylation, Down-Regulation, Drug Resistance, Neoplasm, Female, G2 Phase, Gene Silencing, Humans, Ovarian Neoplasms, Paclitaxel, Protein-Serine-Threonine Kinases, RNA Interference, Transcriptional Activation, Transfection|
|Additional Information :||©2011 American Association for Cancer Research. This is the author's accepted version.|
|Depositing User :||Symplectic Elements|
|Date Deposited :||28 Jun 2012 11:46|
|Last Modified :||23 Sep 2013 19:32|
Actions (login required)
Downloads per month over past year